NCT07654283
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
Not Yet Recruiting
PHASE2Ages 18–65InterventionalTreatmentAusperBio Therapeutics Inc.
~70 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:AHB-137
At a glance
Recruiting sites
0 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ)
Measured over 24 Weeks post AHB-137 treatment (Week 48)
Conditions
Where it's being run
9 sites across 9 statesCalifornia1
Maryland1
New York1
Texas1
Alberta1
France1
Italy1
Spain1
Study leadership
- Audrey Lau, MD, PhD · STUDY_DIRECTOR · AusperBio Therapeutics Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ)24 Weeks post AHB-137 treatment (Week 48)